TY - JOUR AU - Pulido, Marina AU - Roubaud, Guilhem AU - Cazeau, Anne-Laure AU - Mahammedi, Hakim AU - Vedrine, Lionel AU - Joly, Florence AU - Mourey, Loic AU - Pfister, Christian AU - Goberna, Alejandro AU - Lortal, Barbara AU - Bellera, Carine AU - Pourquier, Philippe AU - Houédé, Nadine PY - 2018 DA - 2018/02/17 TI - Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer JO - BMC Cancer SP - 194 VL - 18 IS - 1 AB - Bladder cancer is the 7th cause of death from cancer in men and 10th in women. Metastatic patients have a poor prognosis with a median overall survival of 14 months. Until recently, vinflunine was the only second-line chemotherapy available for patients who relapse. Deregulation of the PI3K/AKT/mTOR pathway was observed in more than 40% of bladder tumors and suggested the use of mTOR as a target for the treatment of urothelial cancers. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-018-4059-5 DO - 10.1186/s12885-018-4059-5 ID - Pulido2018 ER -